35,000 Cytokinetics, Incorporated $CYTK Shares Acquired by Impax Asset Management Group plc

Impax Asset Management Group plc grew its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 21.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 200,000 shares of the biopharmaceutical company’s stock after buying an additional 35,000 shares during the quarter. Impax Asset Management Group plc owned about 0.16% of Cytokinetics worth $13,182,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Pictet Asset Management Holding SA grew its holdings in Cytokinetics by 18.4% during the third quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company’s stock worth $90,569,000 after acquiring an additional 214,060 shares during the period. Fisher Asset Management LLC raised its position in Cytokinetics by 10.1% in the third quarter. Fisher Asset Management LLC now owns 818,832 shares of the biopharmaceutical company’s stock worth $53,969,000 after acquiring an additional 75,135 shares in the last quarter. ADAR1 Capital Management LLC raised its position in Cytokinetics by 17.1% in the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company’s stock worth $41,692,000 after acquiring an additional 92,390 shares in the last quarter. Candriam S.C.A. lifted its holdings in Cytokinetics by 39.3% in the third quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company’s stock valued at $40,841,000 after acquiring an additional 174,320 shares during the period. Finally, Siren L.L.C. acquired a new stake in Cytokinetics in the first quarter valued at $40,466,000.

Insider Transactions at Cytokinetics

In other Cytokinetics news, insider Jeffrey Hessekiel sold 15,106 shares of the company’s stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $52.62, for a total value of $794,877.72. Following the sale, the insider owned 92,837 shares of the company’s stock, valued at approximately $4,885,082.94. This represents a 13.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Robert Blum sold 7,500 shares of the firm’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $53.53, for a total value of $401,475.00. Following the completion of the transaction, the chief executive officer owned 278,544 shares of the company’s stock, valued at approximately $14,910,460.32. This represents a 2.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 201,032 shares of company stock valued at $13,320,502 in the last three months. 2.60% of the stock is owned by company insiders.

Cytokinetics Price Performance

Shares of NASDAQ:CYTK opened at $51.32 on Thursday. The firm has a market capitalization of $7.15 billion, a price-to-earnings ratio of -8.50 and a beta of 0.45. The business’s 50 day simple moving average is $62.79 and its 200-day simple moving average is $69.60. Cytokinetics, Incorporated has a 12 month low of $51.00 and a 12 month high of $88.31.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.06. The firm had revenue of $47.56 million during the quarter, compared to analysts’ expectations of $41.88 million. During the same period in the previous year, the business earned ($2.55) earnings per share. The business’s revenue for the quarter was up 2356.5% on a year-over-year basis. On average, equities analysts anticipate that Cytokinetics, Incorporated will post -5.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CYTK shares. Needham & Company LLC boosted their target price on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Citizens Jmp increased their price target on shares of Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a report on Friday, August 7th. Morgan Stanley upgraded shares of Cytokinetics from an “overweight” rating to a “buy” rating in a report on Tuesday, September 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a research note on Friday, September 11th. Finally, Wall Street Zen raised shares of Cytokinetics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $106.67.

View Our Latest Stock Report on CYTK

Cytokinetics Profile

(Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Recommended Stories

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.